Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women

NCT00040014 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: exemestane

Sponsor

Pfizer